UT
Uvantis Therapeutics, Inc.
SEC filingBiotechnology · Columbia, MD
Amount raised$100Ksold at filing
Total offering$5M$4.9M still open
Investors in the raise1count reported to the SEC
FiledSep 23, 2026first sale Sep 10, 2026
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Jonathan YoungDirector
Edward WooDirector
William SheahanDirector
Paul GiannascaExecutive Officer
Jeffrey CollinsExecutive Officer
Executive officers, directors and promoters as listed on the Form D.